Natural Product-based Synthetic Drug Molecules in Alzheimer's Disease

Therapeutic & Theranostic Agents
1. Auflage 2023
ISBN: 978-981-99-6037-8
Verlag: Springer

Buch, Englisch, 447 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 857 g

This book illustrates the importance of natural products as the source for the development of novel drugs for the treatment of neurodegenerative disorders, including Alzheimer's disease. It also highlights the role of reactive oxygen species and altered metal homeostasis in the progression of Alzheimer’s disease and examines the potential of antioxidants and anti-chelating agents in the clinical intervention of neurodegenerative diseases. The book also discusses the role of neuroinflammation in the pathogenesis of Alzheimer’s disease. The chapters provide information about the drug targets, progress in the development of natural product-based therapeutics, biomarkers, fluorescent diagnostic tools, and theranostic for Alzheimer's disease. The book also provides information about the design and synthesis of natural product-based derivatives against the various targets of Alzheimer's disease including epigenetic targets and the metal dyshomeostasis hypothesis. Cutting across different disciplines, this book is a valuable source for neuroscientists, chemical biologists, pharmaceutical researchers, and synthetic biologists.

Zielgruppe

Research

Autoren/Hrsg.

Sharma, Abha

Modi, Gyan Prakash

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft

Inhaltsverzeichnis

Section 1: Introduction of Alzheimer’s Disease.- Chapter 1: Alzheimer’s disease and drug targets.- Chapter 2: Oxidative stress and metals in Alzheimer’s disease.- Chapter 3: Neuroinflammation in Alzheimer’s disease.- Section 2:  Biomarkers and Diagnosis in Alzheimer’s Disease.- Chapter 4: Biomarkers of Alzheimer’s disease.- Chapter 5: Naturally inspired fluorescent organic molecules as diagnostic and theranostic tools in Alzheimer’s disease.- Chapter 6: Nanostructure-based molecules as diagnostic and theranostic tools in AD.- Section 3:  Drug derivatives: A strategy for new multifunctional drug development for Alzheimer’s Disease.- Chapter 7: Approved cholinesterase inhibitors-based derivatives: Synthesis and their biological evaluation.- Chapter 8: Memantine-based derivatives: Synthesis and their biological evaluation.- Section 4: Natural molecules inspired novel derivatives for Alzheimer’s Disease.- Chapter 9: Huperzine-based derivatives: Design, synthesis, and anti-Alzheimer activity.- Chapter 10: Polyphenol: Development of polyphenol-inspired derivatives targeting pathological factors of AD.- Chapter 11: Flavonoid-based derivatives for modulating various targets of Alzheimer’s disease.- Chapter 12: Vitamin-based derivatives for the management of Alzheimer’s disease.- Section 5: Metal dyshomeostasis: A hypothesis for developing drugs for the treatment of Alzheimer’s disease.- Chapter 13: Metal chelators as a potential therapeutic agent for Alzheimer’s disease.- Chapter 14: Ferroptosis modulators: A potential therapeutic target in Alzheimer’s disease.- Section 6. Natural products/Synthetic molecules as epigenetic modulators in Alzheimer’s disease.- Chapter 15. Sirtuin modulator: Design, synthesis, and biological evaluation.- Chapter 16. Histone deacetylase Inhibitors: Design, synthesis, and biological evaluation.

Über Autor(innen)

Dr. Abha Sharma is working as an associate professor in the department of medicinal chemistry at National Institute of Pharmaceutical Education and Research, Raebareli, India. She earned her Ph.D. from the Defence Research and Development Establishment (awarded by Jiwaji University), Gwalior, India, 2006. She has worked at Indian Institute of Toxicology Research (IITR), Lucknow as a research associate for more than three and a half years. Her research area includes design and synthesis of molecules for the treatment of Alzheimer’s disease and the development of sensors/probes for the detection of analytes/biomarkers of central nervous system diseases like AD. She published more than 40 papers in high-impact journals, several book chapters, and filed patents. She has served as a referee for a number of international journals and several students have completed their research projects under her guidance.

Dr. Gyan Prakash Modi is working as an assistantprofessor in the department of pharmaceutical engineering and technology, Indian Institute of Technology (BHU), Varanasi, India. He earned a Ph.D. from the department of pharmaceutical sciences, Wayne State University, Detroit, Michigan, USA, in 2013, followed by postdoctoral training at Brandeis University, Waltham, Massachusetts, USA. His research area includes drug development for neurodegenerative diseases, inhibitor design, and the development of novel (near-infrared) NIR probes targeting various chronic central nervous system diseases like Alzheimer's disease (AD). He published nearly 25 research papers in high-impact journals and filed several patents, including four US patents in medicinal chemistry. He has been selected as a young investigator to attend YIM 2019 organized by India Bioscience at IIT Guwahati, he is also the recipient of several awards including outstanding scientist in medicinal chemistry, Venus international foundation.